EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Accurate and comprehensive evaluation of O6‐methylguanine‐DNA methyltransferase promoter methylation by nanopore sequencing

Skarphedinn Halldorsson iD, Richard Mark Nagymihaly, Areeba Patel, Petter Brandal, Ioannis Panagopoulos, Henning Leske, Marius Lund-Iversen, Felix Sahm iD, Einar O Vik-Mo

Neuropathology and Applied Neurobiology · 2024

DOI: 10.1111/nan.12984 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropathology and Applied Neurobiology, 2024. Verfasst von Skarphedinn Halldorsson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vilhelm Magnus Laboratory, Institute for Surgical Research, Department of Neurosurgery, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: DNA Methylation, Nanopore Sequencing, Promoter Regions, Genetic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Regional Health Authorities, Consejería de Sanidad y Política Social, Comunidad Autónoma de la Región de Murcia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The methylation status of the O6‐methylguanine‐DNA methyltransferase ( MGMT ) promoter region is essential in evaluating the prognosis and predicting the drug response in patients with glioblastoma. In this study, we evaluated the utility of using nanopore long‐read sequencing as a method for assessing methylation levels throughout the MGMT CpG‐island, compared its performance to established techniques and demonstrated its clinical applicability.

Methods

We analysed 165 samples from CNS tumours, focusing on the MGMT CpG‐island using nanopore sequencing. Oxford Nanopore Technologies (ONT) MinION and PromethION flow cells were employed for single sample or barcoded assays, guided by a CRISPR/Cas9 protocol, adaptive sampling or as part of a whole genome sequencing assay. Methylation data obtained through nanopore sequencing were compared to results obtained via pyrosequencing and methylation bead arrays. Hierarchical clustering was applied to nanopore sequencing data for patient stratification.

Results

Nanopore sequencing displayed a strong correlation (R 2 = 0.91) with pyrosequencing results for the four CpGs of MGMT analysed by both methods. The MGMT ‐STP27 algorithm's classification was effectively reproduced using nanopore data. Unsupervised hierarchical clustering revealed distinct patterns in methylated and unmethylated samples, providing comparable survival prediction capabilities. Nanopore sequencing yielded high‐confidence results in a rapid timeframe, typically within hours of sequencing, and extended the analysis to all 98 CpGs of the MGMT CpG‐island.

Conclusions

This study presents nanopore sequencing as a valid and efficient method for determining MGMT promotor methylation status. It offers a comprehensive view of the MGMT promoter methylation landscape, which enables the identification of potentially clinically relevant subgroups of patients. Further exploration of the clinical implications of patient stratification using nanopore sequencing of MGMT is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationNanopore SequencingPromoter Regions, GeneticHumansCpG IslandsTumor Suppressor ProteinsDNA Modification MethylasesDNA Repair EnzymesBrain NeoplasmsFemaleMaleGlioblastomaAged

Stichwörter der Autor:innen

CRISPR/Cas9MGMT promoter methylationNanopore sequencingglioblastoma

Substanzen

Tumor Suppressor ProteinsDNA Modification MethylasesMGMT protein, humanDNA Repair Enzymes

Autor:innen und Institutionen

  • Vilhelm Magnus Laboratory, Institute for Surgical Research, Department of Neurosurgery, Oslo University Hospital, Oslo, Norway.
  • Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.
  • CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
  • Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Department of Pathology, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Skarphedinn Halldorsson, Felix Sahm

Förderung

  • Regional Health Authorities
  • Consejería de Sanidad y Política Social, Comunidad Autónoma de la Región de Murcia

Zitieren

APA

Halldorsson, S., Nagymihaly, R. M., Patel, A., Brandal, P., Panagopoulos, I., Leske, H., Lund-Iversen, M., Sahm, F., & Vik-Mo, E. O. (2024). Accurate and comprehensive evaluation of O6‐methylguanine‐DNA methyltransferase promoter methylation by nanopore sequencing. Neuropathology and Applied Neurobiology. https://doi.org/10.1111/nan.12984

Vancouver

Halldorsson S, Nagymihaly RM, Patel A, Brandal P, Panagopoulos I, Leske H, et al. Accurate and comprehensive evaluation of O6‐methylguanine‐DNA methyltransferase promoter methylation by nanopore sequencing. Neuropathology and Applied Neurobiology. 2024. doi:10.1111/nan.12984

BibTeX
@article{Halldorsson2024,
  author = {Halldorsson, Skarphedinn and Nagymihaly, Richard Mark and Patel, Areeba and Brandal, Petter and Panagopoulos, Ioannis and Leske, Henning and Lund-Iversen, Marius and Sahm, Felix and Vik-Mo, Einar O},
  title = {Accurate and comprehensive evaluation of O6‐methylguanine‐DNA methyltransferase promoter methylation by nanopore sequencing},
  journal = {Neuropathology and Applied Neurobiology},
  year = {2024},
  doi = {10.1111/nan.12984}
}
Kostenlos starten →